MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

Not Applicable
Completed
Conditions
Osteoarthritis of the Knee
Interventions
Drug: Placebo
First Posted Date
2011-09-08
Last Posted Date
2020-12-31
Lead Sponsor
Pfizer
Target Recruit Count
408
Registration Number
NCT01430559
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

🇨🇳

Anhui Province Hospital, Hefei, Anhui, China

🇨🇳

The First Affiliated Hospital of Shantou Medical Collage, Shantou City, Guangdong, China

and more 22 locations

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2011-09-07
Last Posted Date
2012-04-12
Lead Sponsor
Pfizer
Target Recruit Count
29
Registration Number
NCT01429740
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Phase 3
Completed
Conditions
Chronic Noncancer Pain
Interventions
First Posted Date
2011-09-05
Last Posted Date
2016-11-21
Lead Sponsor
Pfizer
Target Recruit Count
395
Registration Number
NCT01428583
Locations
🇺🇸

Crossroads Research, Owings Mills, Maryland, United States

🇺🇸

Drug Study Institute, Jupiter, Florida, United States

🇺🇸

Sarasota Pain Medicine Research, Sarasota, Florida, United States

and more 29 locations

Systematic Review And Meta-Analysis Of Psoriasis Treatments.

Completed
Conditions
Psoriasis
First Posted Date
2011-08-29
Last Posted Date
2018-12-03
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT01425138

A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

Phase 3
Completed
Conditions
Gaucher Disease
Interventions
First Posted Date
2011-08-23
Last Posted Date
2023-04-19
Lead Sponsor
Pfizer
Target Recruit Count
19
Registration Number
NCT01422187

Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.

Completed
Conditions
Ankylosing Spondylitis
Interventions
First Posted Date
2011-08-22
Last Posted Date
2014-12-12
Lead Sponsor
Pfizer
Target Recruit Count
80
Registration Number
NCT01421303
Locations
🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2011-08-22
Last Posted Date
2016-10-24
Lead Sponsor
Pfizer
Target Recruit Count
34
Registration Number
NCT01421043
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Phase 3
Completed
Conditions
Juvenile Idiopahtic Arthritis
Interventions
First Posted Date
2011-08-22
Last Posted Date
2022-11-14
Lead Sponsor
Pfizer
Target Recruit Count
109
Registration Number
NCT01421069
Locations
🇳🇴

Depart. of Rheumatology, Oslo, Norway

🇸🇮

University Medical Centre Ljubljana, University Children's Hospital, Ljubljana, Slovenia

🇮🇹

Centro di Ricerca Clinica - Fondazione dell'Universita' degli Studi "G. D'Annunzio", Chieti Scalo, Italy

and more 32 locations

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Phase 2
Terminated
Conditions
Endometrial Neoplasms
Interventions
First Posted Date
2011-08-19
Last Posted Date
2019-01-08
Lead Sponsor
Pfizer
Target Recruit Count
67
Registration Number
NCT01420081
Locations
🇺🇸

University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States

🇨🇦

Princess Margaret Hospital, Toronto, Ontario, Canada

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 44 locations

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

Phase 1
Completed
Conditions
Renal Impairment
Interventions
First Posted Date
2011-08-17
Last Posted Date
2012-10-01
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT01419041
Locations
🇺🇸

Pfizer Investigational Site, Saint Paul, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath